[1] Six DA, Dennis EA.The expanding superfamily of phospholipase A2 enzymes: classification and characterization[J]. Biochimi Biophys Acta, 2000, 1488(1-2):1-19. [2] 赵娟, 李相军, 孙波, 等. 维生素D3 联合高脂饲料建立大鼠动脉粥样硬化模型[J]. 实用医学杂志, 2009, 25(21): 3569-3571. [3] 温进坤, 韩梅, 杜玮南, 等. 一种快速建立大鼠动脉粥样硬化模型的实验方法[J]. 中国老年学杂志, 2001, 21(1): 50-52. [4] 郭啸华, 刘志红, 李恒, 等. 高糖高脂饮食诱导的 2 型糖尿病大鼠模型及其肾病特点[J]. 中国糖尿病杂志, 2002, 10(5): 290-294. [5] Schmid K, McSharry WO, Pameijer CH, et al. Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta[J]. Atherosclerosis, 1980, 37(2): 199-210. [6] Fleckenstein-Grün G, Thimm F, Luley C, et al.Differentiation between calcium-and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists[J]. J Cardiovasc Pharmacol, 1991, 18:1-9. [7] 吴开云, 高摄渊. 维生素D诱发大鼠动脉粥样硬化的实验研究[J]. 解剖学报, 1996, 27(2):133-135. [8] Bennani-Kabchi N, Kehel L, El Bouayadi F, et al.New model of atherosclerosis in insulin resistant sand rats: hypercholesterolemia combined with D2 vitamin[J]. Atherosclerosis, 2000, 150(1):55-61. [9] Ross R.Atherosclerosis-an inflammatory disease[J]. N Engl J Med, 1999, 340(2):115-126. [10] Devaraj S, Xu DY, Jialal I.C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells implications for the metabolic syndrome and atherothrombosis[J]. Circulation, 2003, 107(3):398-404. [11] Ghesquiere S, Gijbels M, Anthonsen M, et al.Macrophage specific overexpression of group IIa sPLA2 increases atheroscIerosis and enhances collagen deposition[J]. J Lipid Res, 2005, 46(2):201-210. [12] 王晓辉, 颜光涛. cPLA2α炎性反应中信号转导的“重量级”分子[J]. 中国危重病急救医学, 2004, 16(6):378-380. [13] 郭朝阳,隋少玉,郭朝晖,等. 脂蛋白脂酶活性与老年 2 型糖尿病关系的研究[J]. 中国老年学杂志,2004,24(6): 510-511. [14] 杨振华, 王瑞英, 仝志强, 等. 2 型糖尿病患者餐后血脂反应及脂蛋白脂酶活性变化的研究[J]. 临床荟萃, 2008, 23(3):169-173. [15] Tan G D, Olivecrona G, Vidal H, et al.Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone[J]. Diabetologia, 2006, 49(10):2412-2418. |